News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

June 7, 2023

Pharmaceutical Executive

Pharmaceutical Executive: June 2023
Volume43
Issue 6

Pharma Trends & Trust

Author(s):

Meg Rivers

This month, we deliver deep dives into the industry's commercial output and outlook and how drugmakers are faring in their public trust mandate—two areas where respective growth pursuits can often go hand-in-hand.

Meg Rivers

Every year in June, Pharmaceutical Executive® shares what we call our Pharma 50, which details the top 50 global biopharma companies based on the latest full-year prescription drug sales. The data for the new list was again provided in partnership by Evaluate Ltd. Michael Christel, group managing editor, dives into market trends around topics related to commercial data, emerging treatment markets, as well as outlooks for the future.

There are a few notable shifts in the top 10 and top 20 rankings—as well as a few new entrants to the overall ledger. Also explored are the multitude of factors likely to reshape the rankings in the coming years, including the impact of M&As, legislation, patent expiries, etc. This is an article you won’t want to miss.

In an accompanying story, experts from WittKieffer discuss the efforts companies are—and are not—making to engender the public’s trust. While most companies say they value the trust of the public (and their employees), not everyone is making the same efforts (or not all organizations are making effective changes). For those making strides to prioritize trust, a few of the tactics that have proven successful include starting new roles, forming committees, leading with purpose, and having increased transparency.

This month, I personally had the pleasure of speaking with Jag Dosanjh, president of US neuroscience and eye care for AbbVie and Healthcare Businesswomen’s Association’s (HBA’s) 2023 honorable mentor of the year. Dosanjh shared with me in an interview how he values listening. One of my favorite quotes is: “If you can listen well, you can learn well.” This had me thinking of the WittKieffer story and how, in order to understand the values of others (which is imperative to know in order to ethically gain their trust), you must first listen.

Another topic of relevance lately is—you guessed it—artificial intelligence (AI). I don’t know about you all, but I’ve read my fair share of content on AI lately. But Sharlene Jenner, vice president of engagement strategy for AbelsonTaylor, provides a unique spin on the subject, diving into the potential impact of AI on pharma marketing. The article wasn’t just, “Here is how AI is amazing and will change pharma for the better,” but it provided both potential pros of this technology along with some cautionary points as to the potential impacts of AI, especially when it comes to leveraging data.

I also found it interesting—and more than mildly alarming—how the author noted the use of AI could lead to fake news articles. As ever, we as readers must be hypervigilant. And those of us in the pharma industry must be equally hypervigilant to ensure quality when implementing new technology.

There are, of course, many other incredible stories and columns in this issue. Please give them a read and let me know at pharmexec@mjhlifesciences.com if there are topics you really enjoyed or additional topics that you’d like to see us cover.

Download Issue PDF
Articles in this issue

Image Credit: © FrankBoston - © FrankBoston - stock.adobe.com.
2023 Pharm Exec Top 50 Companies
Great Leaders Listen
Great Leaders Listen
Image Credit: © lidiia - © lidiia - stock.adobe.com.
Measuring Pharma’s Trust Performance
Embracing Generative AI: Why Its Disruption is Positive for Pharma
Embracing Generative AI: Why Its Disruption is Positive for Pharma
Tapping NPs and PAs in Life Sciences Marketing
Tapping NPs and PAs in Life Sciences Marketing
The Quest to Fully Address Prescription Drug Affordability
The Quest to Fully Address Prescription Drug Affordability

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 22nd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 22nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 22nd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 22nd 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
© WESTOCK - © WESTOCK - stock.adobe.com
August 22nd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 22nd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 22nd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 22nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 22nd 2025

Lighthouse Pharmaceuticals Awarded $49.2 Million Grant from NIA to Advance Phase 2 study of LHP588

Nicholas Jacobus
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 22nd 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
© WESTOCK - © WESTOCK - stock.adobe.com
August 22nd 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 22nd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.